\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Antihyperlipidemic Activity of Rhynchosia Beddomei whole Plant: An in Vitro, in Vivo and in Silico Approach},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{1970-01-01 (revised: 01 January 1970)}
\def\TheID{\makeatother }
\def\TheDate{1970-01-01}
\title{Antihyperlipidemic Activity of Rhynchosia Beddomei whole Plant: An in Vitro, in Vivo and in Silico Approach}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \affil[1]{  }

\renewcommand\Authands{ and }

\date{\small \em Received: 1 January 1970 Accepted: 1 January 1970 Published: 1 January 1970}

\maketitle


\begin{abstract}
        




\end{abstract}


\keywords{}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\begin{textblock*}{10cm}(1.05cm,3cm)
{{\textit{CrossRef DOI of original article:}} \underline{}}
\end{textblock*}\let\tabcellsep& 	 	 		 
\section[{I. INTRODUCTION}]{I. INTRODUCTION}\par
Hyperlipidaemia, commonly known as hypercholesterolemia or hyperlipoproteinemias, is a condition when there are abnormally high levels of fats in the blood. The structure and functionality of blood-circulating cholesterol is complex. According to \hyperref[b0]{(Ankur et al., 2012)}, TGs are quickly recycled, deposited in adipocytes, absorbed from the intestine, or processed in hepatic tissue. When endothelial cells begin to suffer damage from atherosclerotic abrasion, cholesterol crystals are discovered. Increased blood lipids (LDL) have been proven to cause atherosclerosis, while epidemiological data has shown that high HDL levels have a protective effect. The greatest risk factor for artery hardening and narrowing is hyperlipidemia. Additional issues include thrombosis, elevated blood pressure, weight gain, and T2DM \hyperref[b3]{(Desu and Saileela, 2013)}. High fat diet and Dexamethasone are used in induction of hyperlipidaemia and Pravastation, Atorvastatin serves as standard in our present study. The healthcare system is structured in such a way that natural remedies are now widely perceived as inferior or something that people use when they cannot afford modern medicine.\par
Rhynchosia beddomei called as adavi kandi and vendaku, found in dry deciduous forests. It is rampant in South India; originate in AP and Karnataka. The leaves of Rhynchosia beddomei have abortifacient, antibacterial, antifungal, antidiabetic hepatoprotective properties and are also used for healing London Journal of Research in Science: Natural and Formal wounds, cuts, boils and rheumatic pains by adivasi tribes. Root decoction is applied on chronic sores to keep off infection due to airborne diseases. A liniment prepared from the root is applied to reduce the pain near swollen wounds. The crushed stem parts are boiled in the sesame oil and used externally to cure sprains. The leaf paste is used as an antidote to treat insect bites. The aim of our study is to evaluate anti-hyperlipidemic activity of the whole plant extract of Rhynchosia beddomei in Wistar Albino rats and to execute in-silico analysis. 
\section[{II. MATERIALS AND METHODS}]{II. MATERIALS AND METHODS}\par
All the chemicals used in the present study were procured from Sigma-Aldrich, Loba Chemie, Merck, Sdfine-Chem, Himedia and Spectrochem. 
\section[{Plant collection \& drying}]{Plant collection \& drying}\par
Rhynchosia beddomei whole plant procured, prepared and referred for certification which were verified by Dr. K. Madhava Chetty, botanist, S.V University, Tirupati. Whole plant, cleaned under running water to remove debris and dried in shade. The dried plant material is then made into a coarse powder and was subjected to further steps. 
\section[{Preparation of Plant Extract}]{Preparation of Plant Extract}\par
The powdered plant material was successively extracted in 500 ml of methanol using Soxhlet extraction and plant material was suspended in the round bottomed flask containing extraction solvent. This was then equipped by a condenser and flask was then heated; active constituents of extract get into the fluid. The finale of the extraction process source was filtered. The excess was vaporized and extracts were then kept in desiccators to remove remaining moisture, if extant, and finally stored in air tight ampoules at 4°C until used. 
\section[{Preliminary phytochemical screening}]{Preliminary phytochemical screening}\par
Preliminary phytochemical screening of the methanolic whole plant extract of R. beddomei (MERB) was qualitatively tested for the presence of phytochemical constituents such as alkaloids, flavonoids, terpenoids, phenols, tannins etc., 
\section[{Antihyperlipidemic Activity}]{Antihyperlipidemic Activity} 
\section[{In vitro HMG-CoA reductase activity}]{In vitro HMG-CoA reductase activity}\par
The concentration of the purified human enzyme stock solution was 0.52-0.85 mg protein/mL. Pravastatin was castoff as reference. To characterize HMG-CoA reductase inhibition under defined assay conditions, reactions containing 4 ?L of NADPH (to obtain a final concentration of 400 ?M) and 12 ?L of HMG-CoA substrate (to obtain a final concentration of 400 ?M) in a final volume of 0.2 mL of 100 mM potassium phosphate buffer, pH 7.4 (containing 120 mM KCl, 1 mM EDTA, and 5 mM DTT), were initiated (time 0) by the addition of 2 ?L of the catalytic domain of human recombinant HMG-CoA reductase and incubated at 37 °C in presence or absence (control) of 1 ?L aliquots of drugs dissolved in DMSO. The rates of NADPH consumed were monitored every 20 sec up to 15 min spectrophotometrically. IC 50 value was calculated and the \% inhibitory enzymatic activity was calculated using the formula (Suvarchala et al., 2015). 
\section[{In vivo Anti-hyperlipidemic Activity}]{In vivo Anti-hyperlipidemic Activity} 
\section[{High fat diet induced hyperlipidaemia in rats}]{High fat diet induced hyperlipidaemia in rats}\par
High cholesterol diet was prepared by mixing cholesterol 2\%, sodium cholate 1\% and coconut oil 2\%, with powdered standard animal food. The diet which was prepared as pellets was placed in the cage and administered for 20 days. Adult Wistar albino rats were administered with corresponding treatments for one month. They were divided into 5 groups with 6 animals per group. Study design of High fat diet induced hyperlipidaemia method is Group -I serves as Control (Normal saline) were as Group -II received HFD, Group -III received HFD and methanolic extract of Rhynchosia beddomei (300mg/kg, p.o) and Group -IV received HFD and atorvastatin (10 mg/kg/day p.o) (Suvarchala et al., 2015). 
\section[{Biochemical investigations for body fat}]{Biochemical investigations for body fat}\par
The serum triglycerides and HDL (High Density Lipoproteins) and total cholesterol were measured using span diagnostic kit. TC, TG and High-Density Lipoproteins profiles were estimated using standard monograph. 
\section[{Measurement of cardiac disorder threat issue}]{Measurement of cardiac disorder threat issue}\par
Atherogenic index (AI), which is a measure of the atherogenic potential of an agent, was calculated using the formula and the results were tabulated.\par
Atherogenic Index (AI) = LDL -cholesterol/HDL -cholesterol \% Protection = AI of control-AI of treated group ×100 Atherogenic Index of control 
\section[{Dexamethasone-induced hyperlipidaemia in rats}]{Dexamethasone-induced hyperlipidaemia in rats}\par
To induce hyperlipidaemia, dexamethasone, (a glucocorticoid excess is known to evoke plasma lipid elevation) in the dose of 10 mg/kg/day, s.c. was administered to Wistar rats for 8 days and animals were divided into five groups each group containing six rats. After the induction of hyperlipidaemia, MERB were given to the rats for 8 days at a dose of 300 mg/kg and on 9 th day, after overnight fasting blood was collected from retro-orbital plexus for the study of biochemical parameters. Study design of High fat diet induced hyperlipidaemia method is Group-I serves as Control (Normal saline) were as Group -II received dexamethasone 10 mg/kg, b.w., s.c., Group -III received dexamethasone 10 mg/kg, b.w., s.c. and methanolic extract of Rhynchosia beddomei (300 mg/kg, p.o) and Group -IV received HFD and atorvastatin (10 mg/kg/day p. o) (Suvarchala et al., 2015). 
\section[{In silico analysis 2.6.1 Molecular Docking Studies}]{In silico analysis 2.6.1 Molecular Docking Studies}\par
Molecular docking is an attractive scaffold to understand drug bimolecular interactions for rational drug design and discovery. Molecular docking generates different possible adduct structures that are ranked and grouped together using a scoring function in the software. The main objective of molecular docking is to attain ligand-receptor complex with optimized conformation and with the intention of possessing less binding free energy \hyperref[b10]{(Suvarchala et al., 2021)}. Molecular docking performed with mCule online tool.\par
London Journal of Research in Science: Natural and Formal 
\section[{Structure based drug design}]{Structure based drug design}\par
Initially the protein downloaded in PDB format was prepared in discovery studio by generating attributes of sphere. Water molecules present in both the chains are removed. Later molecules are drawn using chemdraw/Chemsketch in mol format. Protein and ligand were docked against proteins like 3ASX, 6Q2T and 7S5G. Docking indicates that some of our compounds, docked with protein of Squalene synthase Inhibitor (PDB ID: 3ASX), Lanosterol 14 alpha demethylase Inhibitor (PDB ID: 6Q2T) and PCSK9 Inhibitor (PDB ID: 7S5G) 
\section[{Docking results visualization}]{Docking results visualization}\par
The resulting docking poses were visualized through discovery studio. The best docked structures were chosen using glide score function. The more negative the glide score the more favourable the binding. Additionally, the docked ligand poses were visualized and the different ligand receptor interactions were studied (Ganga raju et al., 2021). 
\section[{Ramachandran plot}]{Ramachandran plot}\par
The docked proteins of Squalene synthase Inhibitor (PDB ID: 3ASX), Lanosterol 14 alpha demethylase Inhibitor (PDB ID: 6Q2T) and PCSK9 Inhibitor (PDB ID: 7S5G) protein were validated and evaluated by using procheck by calculating the Ramachandran plot to access the quality of the model by looking into the allowed and disallowed regions of the plot (Ganga raju et al., 2022). The Ramachandran plot shows the phi-psi torsion angles for all residues in the ensemble (except those at the chain termini). The colouring/shading on the plot represents the different regions described by Morris. the darkest areas (here shown in red) correspond to the "core" regions representing the most favourable combinations of phi-psi values. 
\section[{Statistical analyses}]{Statistical analyses}\par
The Results were expressed as the AM ± S.E.M. The significance of the results was calculated using ANOVA and Dunnett's t-test and results were deliberated statistically noteworthy when significant p<0.01, p<0.05 ns-non significant. 
\section[{III. RESULTS AND DISCUSSION}]{III. RESULTS AND DISCUSSION} 
\section[{Preparation of Rhychosia beddomei methanolic extract}]{Preparation of Rhychosia beddomei methanolic extract}\par
The methanolic extract of Rhychosia beddomei was prepared by soxhlation technique. The percentage yield of the extract was calculated by using the following formula.\par
Amount of extract obtained (grams) \% yield of extract = ×100 Amount of the powder used (grams) = 35.43\%. w/w. 
\section[{Preliminary phytochemical screening}]{Preliminary phytochemical screening}\par
Crude extract was then subjected to preliminary phytochemical screening of Rhynchosia beddomei showed the presence of alkaloids, glycosides, steroids, flavonoids, carbohydrates, proteins and tannins.  
\section[{Invitro antihyperlipidemic Activity 3.3.1 In vitro HMG CoA Reductase Inhibitor Activity}]{Invitro antihyperlipidemic Activity 3.3.1 In vitro HMG CoA Reductase Inhibitor Activity}\par
The data of percent inhibition and IC 50 at two dose levels of methanolic extracts of two plants are presented in Table \hyperref[tab_1]{1} indicated that the \% inhibition is increased with increase in dose of plant extract, though proportionate increase was not obtained. Additionally, inhibition data were processed for relative inhibition compared to standard and reported. The processing is done on the lines of expressions of relative bioavailability (\%). Higher the relative inhibition, the greater is the inhibition of HMG CoA reduction. In this study, standard is pravastatin. As expected, pravastatin produced inhibition at lower dose (100 µg/mL). Plant extracts also showed appreciable inhibition at greater doses (500 µg/mL). The methanolic extracts of both plants showed same extent of \% inhibition of the HMG CoA reduction.\par
The IC 50 values of standard and test extracts are compared and the ratio was found to be less by 55\% respectively, for MERB.  
\section[{In vivo Antihyperlipidemic Activity}]{In vivo Antihyperlipidemic Activity}\par
Hyperlipidaemia was induced by giving high cholesterol diet and dexamethasone (10 mg/kg, b.w., s. c) and parameters measured were TC, triglyceride, low density lipoproteins, VLDL, high density lipoprotein levels. Atherogenic index and \% protection were also measured. 
\section[{High fat diet (HFD) induced hyperlipidaemia}]{High fat diet (HFD) induced hyperlipidaemia}\par
Rats fed on HFD is a means for the induction of metabolic syndrome features including distinctive visceral adiposity, dyslipidaemia which are typically associated with human obesity. The rat model of diet-induced obesity is often used to investigate the effects of metabolic syndrome ameliorating agents. The data of cholesterol, triglycerides, LDL, VLDL and HDL levels upon the treatment of Rhynchosia beddomei methanolic extract at one dose level (300 mg/kg, b.w.) are presented in Table2. When HFD is provided to rats, cholesterol, triglycerides, LDL, VLDL levels increased and HDL level decreased from 80 to 100\% within 20 days. MERB were administered and levels decreased within 30 days compared to Disease control group. The standard in the present study is atorvastatin (10 mg/kg, b.w.). As expected, standard produced lower levels of cholesterol, triglycerides, LDL, VLDL and increased HDL levels at 10 mg/kg. The MERB 300 also showed appreciable decrease of cholesterol levels and nearer to the standard value. In the present work, Rhynchosia beddomei was reported to contain ?-sitosterol and stigmasterol. These might be responsible to lower cholesterol in animals fed with HFD.\par
London Journal of Research in Science: Natural and Formal In view of reducing cholesterol by plant extracts and other related parameters, TG, LDL, VLDL was further evaluated. When HFD is provided to rats, triglyceride levels were increased by 80 to 100\% within 20 days and LDL levels were amplified by 300\% within 20 days, VLDL levels were doubled by within 20 days, HDL levels were decreased by 20\% within 20 days in disease group. The plant extract was administered, the triglyceride levels, LDL, VLDL levels decreased compared to control, the test samples of significant in p<0.05 , compared to standard, the samples have significantly different (p<0.01) and HDL increased within 30 days compared to control (p<0.05), when compared to standard the samples are significantly different (p<0.05). 
\section[{Measurement of Cardiac Disorder Threat Issue}]{Measurement of Cardiac Disorder Threat Issue} 
\section[{Atherogenic Index}]{Atherogenic Index}\par
The atherogenic index is obtained based on the knowledge of cholesterol, LDL and HDL values. Thus the index was calculated. The data of atherogenic index upon the treatment of plant extracts at one dose level (300 mg/kg, b.w.) shown in figure, indicated that the atherogenic index remained same for the control up to 30 days. When high fat diet is provided to rats, the atherogenic index was increased by 3 times (300\%) within 20 days. The differences between control and cholesterol control are significant (p<0.05). The plant extracts were administered, the atherogenic index reached the value of control within 30 days, the test samples are significant (p<0.05), when compared to standard, the samples are significantly same (p<0.01). The lower the atherogenic index, the higher is the hypolipidemic activity (of the test extracts). The standard in the present study is atorvastatin (10 mg/kg, b.w.). As expected, atorvastatin produced lower levels of atherogenic index (1) at a dose level of 10 mg/kg. The plant extract also showed appreciable decrease of atherogenic index and nearer to the standard value (p<0.05). 
\section[{Effect on \% protection}]{Effect on \% protection}\par
The percent protection of heart is considered based on the levels are different parameters evaluated so far. In the calculation of atherogenic index, control and cholesterol control values are not included. But in the calculation of percent protection, control values are also included. \% Protection was calculated for the groups treated with MERB 300 mg/kg, b.w. explained in table \hyperref[tab_3]{3}. As observed in the values of atherogenic index, the percent protection is 30 times lower than the standard, when dose-normalized. London Journal of Research in Science: Natural and Formal  
\section[{Dexamethasone induced hyperlipidaemia}]{Dexamethasone induced hyperlipidaemia}\par
Dexamethasone, triggering a disproportion in lipid metabolism leading to hyperlipidaemia \hyperref[b14]{(Wiesenberg et al., 1998)}. Hyperlipidaemia was produced by administering dexamethasone (10 mg/kg, b.w., s. c). The parameters measured were total cholesterol; triglyceride, LDL, VLDL, HDL levels, atherogenic index and percent protection were also measured. The antihyperlipidemic activity was evaluated for MERB.\par
The cholesterol, triglycerides, LDL, VLDL and HDL levels upon the treatment MERB at one dose level (300 mg/kg, b.w.) are presented in Table \hyperref[tab_4]{4} indicated that all levels remained same for the control upto 11 days. When dexamethasone is injected to rats, the cholesterol, TGL, VLDL levels were almost doubled, the LDL levels increased nearly 3½ times and HDL levels were decreased by 5 to 6\% within 11 days. The Methanolic extract of Rhynchosia beddomei extract were administered, the cholesterol, triglycerides, LDL, VLDL levels decreased and HDL levels increased when compared to control, the results of test samples are significant (p<0.05) that indicates the higher is the hypolipidemic activity of the test extract may be due to the presence of phytosterol \hyperref[b1]{(Bopanna et al 1997)}. Any lipid reduction (1\% cholesterol) produces a 2-3\% reduction in CHD risk \hyperref[b15]{(Xu et al 2005)}. The standard, atorvastatin (10 mg/kg, b.w.) produced lower levels of cholesterol. In the present work, Rhynchosia beddomei was reported to contain ?-sitosterol and stigmasterol. These might be responsible for lowering the Lipid levels, though the animals were injected with dexamethasone.  
\section[{Measurement of cardiac disorder threat issue 3.4.2.1 Effect on atherogenic index (AI)}]{Measurement of cardiac disorder threat issue 3.4.2.1 Effect on atherogenic index (AI)}\par
When dexamethasone is provided to rats, the atherogenic index was increased by 3 times within 10 days. The data of atherogenic index upon the treatment of MERB at one dose level (300 mg/kg, b.w.) are presented in Table \hyperref[tab_5]{5}. Atherogenic index remained the same for the control upto 11 days. When the MERB was administered, the atherogenic index decreased within 11 days, compared to control and values are nearer to the standard value standard,  
\section[{Effect on \% protection}]{Effect on \% protection}\par
Percent protection was calculated for the groups treated with MERB 300 mg/kg, b.w. As observed in the values of atherogenic index, the percent protection is 30 times lower than the standard, when dose-normalized. Dexamethasone induced hyperlipidaemia, the animal model effectively used for evaluating the antihyperlipidemic activity of natural products \hyperref[b7]{(Kumar et al., 2007)}. In the present study, treatment with MERB (300 mg/kg) has reduced the serum cholesterol, triglycerides levels and atherogenic index, in dexamethasone treated animals. The extracts inverted the hyperlipidaemia produced by administration of dexamethasone. The low lipoprotein lipase activity in the liver may be responsible for low degradation of lipoprotein, triglycerides and cholesterol. Hence the hyperlipidemic effect of dexamethasone was found to be reversed by MERB, further this was also found to be comparable with that of atorvastatin. In this work, friedelin is proposed to decrease the TC, TG, and LDL-C and increase the HDL-C levels significantly. The methanolic extract of Rhynchosia beddomei contains London Journal of Research in Science: Natural and Formal phytosterol and flavonoids. The high amount of flavonoids complemented the phytosterols which might be accountable for the hypolipidemic effect. It also improves HDL-cholesterol levels and lower atherogenic index. More specifically the presence of friedelin has the added benefit of stimulating the synergistic effect for eliciting the antihyperlipidemic activities.  G score = glide score, Higher the negativity, the more favourable the binding.    
\section[{Ramachandran plot Analysis}]{Ramachandran plot Analysis}\par
Protein 3ASX, 6Q2T and 7S5G were analysed for Ramachandran plot to know amino acid presence in different regions of respective protein tabulated in table 8 and pictorial representation by figure  {\ref 6}.  The standard pravastatin was found to possess 65.0\% inhibition at 100 µg/mL. Graded response is an encouraging observation. The extract lowered the TC, TG, LDL and VLDL, results were consistently observed in two models, also showed appreciable decrease of atherogenic index and nearer to the standard value. Therefore, more research into the use of a methanolic extract of Rhynchosia beddomei whole plant as an alternative therapeutic agent to statins and other medications, but one that has no unwanted side effects, is necessary for the treatment of cardiovascular disorders.\begin{figure}[htbp]
\noindent\textbf{5}\includegraphics[]{image-2.png}
\caption{\label{fig_0}3. 5}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{93}\includegraphics[]{image-3.png}
\caption{\label{fig_1}9 Figure 3 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{4}\includegraphics[]{image-4.png}
\caption{\label{fig_2}Figure 4 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{5}\includegraphics[]{image-5.png}
\caption{\label{fig_3}Figure 5 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-6.png}
\caption{\label{fig_4}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{P{0.30021276595744684\textwidth}P{0.08319148936170213\textwidth}P{0.2712765957446809\textwidth}P{0.1953191489361702\textwidth}}
\tabcellsep \tabcellsep Percentage\tabcellsep \\
\tabcellsep Dose\tabcellsep \tabcellsep \% Relative\\
Test extract/standard\tabcellsep \tabcellsep inhibition\tabcellsep IC 50 (µg/mL)\\
\tabcellsep (µg/mL)\tabcellsep \tabcellsep inhibition\\
\tabcellsep \tabcellsep AM±SEM (n=3)\tabcellsep \\
Methanolic extract of\tabcellsep 100\tabcellsep 43.33 ±0.76\tabcellsep 33.34\\
\tabcellsep \tabcellsep \tabcellsep 150\\
Rhynchosia beddomei\tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep 500\tabcellsep 85 ±0.012\tabcellsep 73.9\\
\tabcellsep 100\tabcellsep 66.86 ± 0.0788\tabcellsep 100\\
Pravastatin (Standard)\tabcellsep \tabcellsep \tabcellsep 75\\
\tabcellsep 500\tabcellsep 100±0.012\tabcellsep 100\end{longtable} \par
 
\caption{\label{tab_1}Table 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2} \par 
\begin{longtable}{P{0.85\textwidth}}
model\end{longtable} \par
 
\caption{\label{tab_2}Table 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{3} \par 
\begin{longtable}{P{0.5378016085790884\textwidth}P{0.18914209115281502\textwidth}P{0.12305630026809652\textwidth}}
\tabcellsep Treatment/Standard\tabcellsep \% Protection,\\
Groups\tabcellsep \tabcellsep \\
\tabcellsep Dose mg/kg, b.w.\tabcellsep AM±SEM, (n=6)\\
I\tabcellsep Control\tabcellsep -\\
II\tabcellsep Cholesterol control\tabcellsep -\\
III\tabcellsep MERB 300\tabcellsep 72.04±0.43 b,A\\
IV\tabcellsep Atorvastatin 10\tabcellsep 72.6±0.56 b\\
\multicolumn{3}{l}{Test groups were compared with control group and standard group. By using Dunnett's t-test significant}\\
\multicolumn{3}{l}{values are expressed as control group (a=p<0.01, b=p<0.05) and standard (A = p < 0.01, B = p <}\\
0.05), ns-non significant.\tabcellsep \tabcellsep \end{longtable} \par
 
\caption{\label{tab_3}Table 3 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{4} \par 
\begin{longtable}{P{0.85\textwidth}}
model\end{longtable} \par
 
\begin{quote}
\par
Test groups were compared with control group, cholesterol control group and standard group. By using Dunnett's t-test significant values are expressed as control group (a=p<0.01, b=p<0.05), cholesterol control (**= p<0.01, *= p<0.05) and standard (A = p < 0.01, B = p < 0.05), ns-non significant.London Journal of Research in Science: Natural and Formal\end{quote}

\caption{\label{tab_4}Table 4 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{5} \par 
\begin{longtable}{P{0.5623922413793103\textwidth}P{0.15387931034482757\textwidth}P{0.13372844827586206\textwidth}}
\tabcellsep Treatment/ Standard\tabcellsep Atherogenic Index\\
Group\tabcellsep \tabcellsep \\
\tabcellsep Dose mg/kg, b.w.\tabcellsep AM±SEM, (n=6)\\
I\tabcellsep Control\tabcellsep 0.93±0.28\\
II\tabcellsep Cholesterol control\tabcellsep 5±0.27 b,A\\
III\tabcellsep MERB 300\tabcellsep 1.23±0.11 a,A\\
IV\tabcellsep Atorvastatin 10\tabcellsep 1.09±0.04 a\\
\multicolumn{3}{l}{Test groups were compared with control group, cholesterol control group and standard group. By using}\\
\multicolumn{3}{l}{Dunnett's t-test significant values are expressed as control group (a=p<0.01, b=p<0.05), cholesterol}\\
\multicolumn{3}{l}{control (**= p<0.01, *= p<0.05) and standard (A = p < 0.01, B = p < 0.05), ns-non significant.}\end{longtable} \par
 
\caption{\label{tab_5}Table 5 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{6} \par 
\begin{longtable}{P{0.5936507936507937\textwidth}P{0.16190476190476188\textwidth}P{0.09444444444444444\textwidth}}
\tabcellsep Treatment/Standard\tabcellsep \% Protection\\
Groups\tabcellsep \tabcellsep \\
\tabcellsep dose, mg/kg, b.w.\tabcellsep AM±SEM (n=6)\\
I\tabcellsep Control\tabcellsep -\\
II\tabcellsep Cholesterol control\tabcellsep -\\
III\tabcellsep MERB 300\tabcellsep 81.2±0.41 a,A\\
IV\tabcellsep Atorvastatin 10\tabcellsep 81±0.74 a\\
\multicolumn{3}{l}{Test groups were compared with control group, cholesterol control group and standard group. By using}\\
\multicolumn{3}{l}{Dunnett's t-test significant values are expressed as control group (a=p<0.01, b=p<0.05), cholesterol control}\\
\multicolumn{3}{l}{(**= p<0.01, *= p<0.05) and standard (A = p < 0.01, B = p < 0.05), ns-non significant.}\end{longtable} \par
 
\caption{\label{tab_6}Table 6 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{7} \par 
\begin{longtable}{P{0.43473282442748085\textwidth}P{0.13842239185750638\textwidth}P{0.13842239185750638\textwidth}P{0.13842239185750638\textwidth}}
Compounds\tabcellsep 3ASX\tabcellsep 6Q2T\tabcellsep 7S5G\\
Quercitin-7-O-methyl ether\tabcellsep -8.4\tabcellsep -6.2\tabcellsep -5.8\\
Isovitexin\tabcellsep -8.5\tabcellsep -6.3\tabcellsep -6.2\\
5,7,3',4'-tetrahydroxy 6-c-?\tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep -7.5\tabcellsep -5.6\tabcellsep -5.9\\
-D-glucopyrynosyl flavone\tabcellsep \tabcellsep \tabcellsep \\
Apigenin\tabcellsep -8.2\tabcellsep -7.0\tabcellsep -6.0\\
Vitexin\tabcellsep -8.3\tabcellsep -6.2\tabcellsep -5.9\\
Vicenin\tabcellsep -8.3\tabcellsep -5.9\tabcellsep -6.3\\
Orientin\tabcellsep -8.1\tabcellsep -5.8\tabcellsep -5.7\\
Isoorientin\tabcellsep -7.9\tabcellsep -6.3\tabcellsep -6.5\\
Lucenin\tabcellsep -8.5\tabcellsep -5.4\tabcellsep -6.1\\
Rutin\tabcellsep -8.8\tabcellsep -5.6\tabcellsep -5.9\\
Rhynchosin\tabcellsep -7.9\tabcellsep -6.9\tabcellsep -6.0\\
Biochanin\tabcellsep -7.7\tabcellsep -7.3\tabcellsep -6.2\\
D-Pinitol\tabcellsep -4.8\tabcellsep -3.5\tabcellsep -3.9\\
D-Inositol\tabcellsep -4.6\tabcellsep -3.5\tabcellsep -4.0\\
Atorvastatin\tabcellsep -7.9\tabcellsep -8.7\tabcellsep -5.4\end{longtable} \par
 
\caption{\label{tab_7}Table 7 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{8} \par 
\begin{longtable}{P{0.5895953757225433\textwidth}P{0.08352601156069364\textwidth}P{0.0884393063583815\textwidth}P{0.0884393063583815\textwidth}}
Residues\tabcellsep 3ASX\tabcellsep 6Q2T\tabcellsep 7S5G\\
Most favourable region (\%)\tabcellsep 94.8\tabcellsep 90.9\tabcellsep 88.4\\
Additional allowed regions (\%)\tabcellsep 5.2\tabcellsep 8.9\tabcellsep 11.2\\
Generously allowed regions (\%)\tabcellsep 0.0\tabcellsep 0.00\tabcellsep 0.0\\
Disallowed regions (\%)\tabcellsep 0.0\tabcellsep 0.3\tabcellsep 0.3\end{longtable} \par
 
\caption{\label{tab_8}Table 8 :}\end{figure}
 			\label{foot_0}\footnote{\label{foot_0} N V L Suvarchala Reddy, Ganga Raju M, M, Mamatha, M. Lakshmi Madhuri Shabnam Kumari Thakur, Pavani K \& G. Kinnera Ratnasri} 			\label{foot_1}\footnote{\label{foot_1} Volume 23 | Issue 10 | Compilation 1.0 © 2023 Great Britain Journal Press Anthyperlipidemic Activity of Rhynchosia Beddomei whole Plant: An in Vitro, in Vivo and in Silico Approach} 			\label{foot_2}\footnote{\label{foot_2} Volume 23 | Issue 10 | Compilation 1.0 © 2023 Great Britain Journal Press Anthyperlipidemic Activity of Rhynchosia Beddomei whole Plant: An in Vitro, in Vivo and in Silico Approach} 		 		\backmatter  			  				\begin{bibitemlist}{1}
\bibitem[ London Journal of Research in Science: Natural and Formal]{b8}\label{b8} 	 		\textit{},  	 	 		\textit{London Journal of Research in Science: Natural and Formal}  		 	 
\bibitem[Desu and Saileela ()]{b3}\label{b3} 	 		‘Anti-hyperlipidemic activity of methanolic extract of Rhinacanthus nasutus’.  		 			Bsr Desu 		,  		 			C H Saileela 		.  	 	 		\textit{Int J Res Pharm Chem}  		2013. 3  (3)  p. .  	 
\bibitem[Bopanna et al. ()]{b1}\label{b1} 	 		‘Antidiabetic and antihyperlipidemic effects of neem seed kernal powder on alloxan diabetic rabbits’.  		 			K N Bopanna 		,  		 			J Kannan 		,  		 			S Gadgil 		,  		 			R Balaraman 		,  		 			S P Rathod 		.  	 	 		\textit{Ind J Pharmacol}  		1997. 29 p. .  	 
\bibitem[Reddy et al. ()]{b11}\label{b11} 	 		‘Antihyperlipidemic activity of Cassia fistula bark using high fat diet induced hyperlipidemia’.  		 			Suvarchala Reddy 		,  		 			Nvl 		,  		 			Pooja Raj 		,  		 			GB 		,  		 			Ganga Raju 		,  		 			M Sneha 		,  		 			J Anarthe 		.  	 	 		\textit{International Journal of Pharmacy and Pharmaceutical Sciences}  		2015. 7  (10)  p. .  	 
\bibitem[Reddy et al. ()]{b12}\label{b12} 	 		‘Antihyperlipidemic activity of methanolic extract of Syzygium alternifolium bark against high-fat diet and dexamethasone induced hyperlipidemia in rats’.  		 			Suvarchala Reddy 		,  		 			Nvl 		,  		 			Swetha Aveti 		,  		 			M Anjum 		,  		 			Ganga Raju 		,  		 			M 		.  	 	 		\textit{Asian Journal of Pharmaceutical and Clinical Research}  		2015. 8  (6)  p. .  	 
\bibitem[Debose-Boyd ()]{b2}\label{b2} 	 		‘Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase’.  		 			R Debose-Boyd 		.  		 \xref{http://dx.doi.org/10.1038/cr.2008.61}{10.1038/cr.2008.61}.  		 \url{https://doi.org/10.1038/cr.2008.61}  	 	 		\textit{Cell Res}  		2008. 18 p. .  	 
\bibitem[Reddy et al. ()]{b10}\label{b10} 	 		‘GC-MS analysis, In silico docking studies and diuretic activity of methanolic extract of Citrus medica l. Leaf in Wistar albino rat model’.  		 			Suvarchala Reddy 		,  		 			Nvl 		,  		 			M Ganga Raju 		,  		 			M Mamatha 		,  		 			Nandini 		.  	 	 		\textit{Bull. Env.Pharmacol. Life Sci}  		2021. 10  (3)  p. .  	 
\bibitem[Ankur et al. ()]{b0}\label{b0} 	 		‘Hyperlipidemia-a deadly pathological condition’.  		 			R Ankur 		,  		 			D Nidhi 		,  		 			R Seema 		,  		 			D Amarjeet 		,  		 			K Ashok 		.  	 	 		\textit{Int J Curr Pharm Res}  		2012. 4  (2)  p. .  	 
\bibitem[Venugopal and Ramakrishna ()]{b13}\label{b13} 	 		‘Indirect assessment of hydroxymethylglutaryl-CoA reductase (NADPH) activity in liver’.  		 			A Venugopal 		,  		 			S Ramakrishna 		.  	 	 		\textit{Clin Chem}  		2005. 21 p. .  	 
\bibitem[Xu et al. ()]{b15}\label{b15} 	 		‘Introduction of hyperglycaemia and dyslipidaemia in the pathogenesis of diabetic vascular complications’.  		 			Y Xu 		,  		 			Z He 		,  		 			G L King 		.  	 	 		\textit{London Journal of Research in Science: Natural and Formal}  		2005. 5  (2)  p. .  	 	 (Curr Diabetic Rep) 
\bibitem[Raju et al. ()]{b5}\label{b5} 	 		‘Natural Compounds as D2 receptor agonist, M4 receptor antagonist and ACHE modulator: Mechanistic and in silico modeling studies’.  		 			Ganga Raju 		,  		 			M 		,  		 			Veena Yadav 		,  		 			N V L Suvarchala Reddy 		,  		 			V 		.  	 	 		\textit{Journal of research in medical and dental science}  		2021. 9  (6)  p. .  	 
\bibitem[Kourounakis and Bavavea (2020)]{b6}\label{b6} 	 		‘New applications of squalene synthase inhibitors: Membrane cholesterol as a therapeutic target’.  		 			A P Kourounakis 		,  		 			E Bavavea 		.  		 \xref{http://dx.doi.org/10.1002/ardp.202000085}{10.1002/ardp.202000085}.  		 32557793.  	 	 		\textit{Arch Pharm}  		2020 Sep. 2000085. 2020 Jun 18. Weinheim. 353  (9) .  	 
\bibitem[Raju et al. ()]{b4}\label{b4} 	 		‘Novel In Silico and In Vivo Insights of Flavonoids as Anti-Diabetic and Anti-Oxidant in Rodent Models’.  		 			Ganga Raju 		,  		 			M 		,  		 			Sony Priyanka 		,  		 			G 		,  		 			Suvarchala Reddy 		,  		 			Nvl 		.  	 	 		\textit{Indian J Pharm Sci}  		2022. 84  (4)  p. .  	 
\bibitem[Sible et al. (2016)]{b9}\label{b9} 	 		‘PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia’.  		 			A M Sible 		,  		 			J J Nawarskas 		,  		 			J R Anderson 		.  		 \xref{http://dx.doi.org/10.1097/CRD.0000000000000102}{10.1097/CRD.0000000000000102}.  		 26886466.  	 	 		\textit{Cardiol Rev}  		2016 May-Jun. 24  (3)  p. .  	 
\bibitem[Kumar et al. ()]{b7}\label{b7} 	 		‘Serum glucose and triglyceride lowering activity of some novel glitazones against dexamethasone-induced hyperlipidaemia and insulin resistance’.  		 			Brp Kumar 		,  		 			T K Praveen 		,  		 			M J Nanjan 		,  		 			M D Karvekar 		,  		 			B Suresh 		.  	 	 		\textit{Ind J Pharmacol}  		2007. 39 p. .  	 
\bibitem[Wiesenberg et al. ()]{b14}\label{b14} 	 		‘Specific activation of the nuclear receptor PPAR? and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthiritic thiazolidinedione derivative GGP 52608’.  		 			I Wiesenberg 		,  		 			M Chiesi 		,  		 			M Missbach 		,  		 			C Spanka 		,  		 			W Pignat 		.  	 	 		\textit{Mol Pharmacol}  		1998. 53 p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
